A industry-backed study estimates potential losses for the Swiss pharma industry from US policies could be in the billions.
US customs policy: Study warns of billions in losses for the pharmaceutical industry
Keystone-SDA
US pharmaceutical policy could prove costly for Switzerland. An industry-backed study estimates that potential losses could reach almost CHF95 billion ($117 billion) by 2040 and warns of consequences for patients.
Generated with artificial intelligence.
This content was published on
Les droits de douane américains pourraient coûter près de 195 milliards de francs à la Suisse, selon une étude. Des effets…
The US may open a trade investigation into Switzerland's pharmaceutical industry, threatening tariffs on $35.5 billion in imports…
Interpharma warns Switzerland may face a US Section 301 trade probe targeting drug pricing, threatening $35.5 billion in pharma…
Boss of Swiss pharma research association bemoans political pressure of drug prices.
Swiss pharma companies warn current pricing rules delay access to new medicines.
Swiss companies invested $27 billion in the US in early 2026 after tariffs dropped from 39% to 15%, with Roche and Novartis…
